Skip to content
Peptigraph home

Tesamorelin and Ipamorelin Together: What Is Known

Tesamorelin and Ipamorelin taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogFDA approved (Egrifta)TesamorelinFDA-approved GHRH analog (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy; visceral fat fell 15.2% versus a 5.0% rise with placebo in a randomized trial.[15]Growth hormoneGHRP (ghrelin receptor agonist)Not FDA approved · research chemicalIpamorelinGhrelin-receptor agonist peptide, not FDA-approved; in a randomized trial after bowel resection, median time to first tolerated meal was 25.3 versus 32.6 hours with placebo.[12]Growth hormone
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 6 results, 2 Oct 2026).

We have no sourced data on taking these two together. Ask the prescriber who manages both.
Each component

Side by side

Showing 9 of 14 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.

FieldTesamorelinIpamorelin
ClassGHRH analogGHRP (ghrelin receptor agonist)
Also calledtesa, Egriftaipa, ipam
FDA statusFDA approved (Egrifta)Not FDA approved · research chemical
Anti-doping detection
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
  • After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
  • A direct-urine screen includes ipamorelin among the peptides it can detect, at 50 to 500 pg/mL.PMID 26578461
Half-life11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR)2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658
Human studies we summarised11 human (11 randomized or controlled) of 12 summarised2 human (2 randomized or controlled) of 12 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 10 mg, 20 mg2 mg, 5 mg, 10 mg
US searches per month165,000 · +188% searches49,500 · +70% searches
Related tools

Sold pre-mixed too

Some vials combine these peptides. The blend calculator shows the dose of each component per draw.

Blend calculator
Tesamorelin + IpamorelinTesamorelin + IpamorelinComparisonTesamorelin vs Ipamorelin

What people search

  • tesamorelin ipamorelin4,400/mo
  • tesamorelin ipamorelin blend3,600/mo
  • tesamorelin and ipamorelin1,300/mo
  • tesamorelin ipamorelin dosage720/mo
  • ipamorelin and tesamorelin590/mo
  • tesamorelin with ipamorelin480/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  4. 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  5. 5EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  6. 6The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  7. 7Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  8. 8The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
  9. 9Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
  10. 10Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
  11. 11Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  12. 12Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  13. 13The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.Physiology & behavior · 2024PMID 39043357Accessed 2 Oct 2026
  14. 14PubMed search: (ipamorelin[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026

Found an error? Report a correction.